List of Vuity drug patents
Vuity is owned by Abbvie Inc.
Vuity contains Pilocarpine Hydrochloride.
Vuity has a total of 2 drug patents out of which 0 drug patents have expired.
Vuity was authorised for market use on 28 October, 2021.
Vuity is available in solution;ophthalmic dosage forms.
Vuity can be used as use of vuity for the treatment of presbyopia in adults.
The generics of Vuity are possible to be released after 24 April, 2039.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10610518 | ABBVIE INC | Presbyopia treatments |
Apr, 2039
(15 years from now) | |
| US11285134 | ABBVIE INC | Presbyopia treatments |
Apr, 2039
(15 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Dosing Schedule (D) | Mar 28, 2026 |
| New Product (NP) | Oct 28, 2024 |
Drugs and Companies using PILOCARPINE HYDROCHLORIDE ingredient
Market Authorisation Date: 28 October, 2021
Treatment: Use of vuity for the treatment of presbyopia in adults
Dosage: SOLUTION;OPHTHALMIC
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic